

# BioLink Weekly Intelligence

Connecting Innovation | Bridging Global Partnerships | Advancing Drug Development

Week of April 1 – April 12, 2026

www.biorichinc.com

## CONTENTS

- 1 Major Licensing Deals | April 1 – April 12, 2026 p. 1
- 2 Top 20 Biopharma 2026 | Strategic Moves & Patent Cliff p. 3
- 3 Executive Opportunities | CEO & CMO Search p. 5
- 4 BD&L Opportunity Board | Buy-Side & Sell-Side Mandates p. 5
- 5 BioRich Out-Licensing Portfolio | 28 Assets Available p. 7

## 1 MAJOR LICENSING DEALS | April 1 – April 12, 2026

BioRich International provides cutting-edge drug discovery and development projects to top global pharmaceutical companies every day. Our BD&L team maintains proactive communication with leading pharma partners worldwide. This intelligence brief covers major licensing activity, strategic industry moves, executive opportunities, funding developments, and BioRich's own out-licensing portfolio.

\$60B+	76%	\$1.3B	\$172M	516+	\$300B
Q1 2026 China	Avg. Deal Size	Avg. Deal 2026	Avg. Upfront	Active Deals	At-Risk Sales

### Quick Summary: Selected Major Deals, April 1–12, 2026

Licensor / Seller	Licensee / Buyer	Asset / Focus	Deal Value	Type	Region
CSPC Pharmaceutical	AstraZeneca	GLP-1/Obesity drug	Up to \$18.5B	License-In	China & Global
RemeGen	AbbVie	Cancer (bispecific antibody)	Up to \$5.6B	License-In	China & Global
Hengrui Pharma	GSK	12 oncology/metabolic candidates	\$12B+	License-In	China & Global
Jacobio Pharma	AstraZeneca	Pan-KRAS inhibitor	Up to \$2.0B	License-In	China & Global
Chia Tai Tianqing	Sanofi	JAK/ROCK (rovadicitnib)	Up to \$1.395B	License-In	China & Global
Suzhou Ribo	Madrigal Pharma	Liver disease programs	Up to \$4.4B	License-In	China & US
Alebund Pharma	R1 Therapeutics	AP306 – CKD dialysis	\$77.5M Ser. A	NewCo/Fund	China & US


### Deal Highlights & Context

- **AstraZeneca – CSPC Pharmaceutical (\$18.5B):** Largest single out-licensing deal in Chinese pharma history. AstraZeneca gains global rights to CSPC's novel GLP-1 receptor agonist for obesity and metabolic diseases.

- **AbbVie – RemeGen (up to \$5.6B):** AbbVie secures rights to RemeGen's lead bispecific antibody program in oncology. With Imbruvica facing its 2027 patent cliff, AbbVie continues aggressive in-licensing to replenish its oncology pipeline.
  - **GSK – Hengrui Pharma (\$12B+):** A landmark multi-asset deal spanning 12 development candidates across oncology and metabolic disease — one of the most diversified licensing agreements of 2026.
  - **AstraZeneca – Jacobio Pharma (\$2.0B):** AstraZeneca in-licenses Jacobio's pan-KRAS inhibitor — one of the most sought-after oncology mechanisms. KRAS inhibitors represent a new frontier in solid-tumor treatment.
  - **Sanofi – Chia Tai Tianqing (\$1.395B):** Sanofi strengthens its inflammation pipeline with a JAK/ROCK dual inhibitor. Upfront: \$135M. Reinforces Western pharma's access to China's deep bench of small molecule innovators.
  - **China Out-Licensing Market:** Chinese biotech out-licensing hit a record \$60B in Q1 2026 alone — 73% YoY — as NMPA approvals accelerate. Average upfront payments surged 230% since 2022, to \$172M per deal.
-

## 2 TOP 20 BIOPHARMA IN 2026 | Strategic Moves & Patent Cliff

### Billions-Dollar Strategic Moves (2025–2026)




- **Eli Lilly – \$2.7B AI Platform Deal:** Lilly partners with AI-driven drug discovery platform to accelerate its cardiometabolic pipeline.
- **AstraZeneca – \$18B AI Innovation Investment:** AZ commits to building the industry's largest AI Innovation Foundation, integrating genomics, real-world data, and ML-powered molecule design.
- **Novartis – \$19B Oncology Expansion:** Deploys capital toward radioligand therapies (RLT) and CAR-T following strong Pluvicto/Kisqali performance.
- **Pfizer – 4 Biotech Acquisitions + Partnerships:** Post-COVID revenue normalization; Pfizer pivots aggressively to external M&A and licensing across oncology, rare disease, and inflammation.
- **Sanofi – \$1.2B Digital Health & Rare Disease:** Accelerates investment in rare disease platforms and digital biomarker discovery ahead of Dupixent's 2031 patent expiry.
- **Market Opportunity:** Over \$300B in drug sales face competition by 2032. BioRich provides innovative discovery projects to these companies daily

### Pharma Patent Cliff: \$300B at Risk by 2032 — The Innovation Imperative

The patent cliff is the single largest driver of external deal-making in 2026. As blockbuster drugs lose exclusivity, companies face revenue gaps internal R&D cannot fill alone. 14 major acquisitions were completed as pharma races to replenish pipelines.

\$300 billion in drug sales at risk by 2032.  
14 major acquisitions in Q1 2026 alone.  
Keytruda. Eliquis. Xeljanz. All facing patent...more



Source: Patent cliff data per company disclosures and industry analysis. Sales figures correspond to 2023 revenues.

Year	Drug	Company	Peak Sales	Therapeutic Area
2026	Eliquis	BMS / Pfizer	\$12.2B	Anticoagulant
2027	Trulicity	Eli Lilly	\$7.1B	Diabetes / GLP-1
2027	Ocrevus	Roche	\$7.1B	Multiple Sclerosis
2028	Keytruda	Merck	\$25.0B	Oncology (PD-1)
2028	Opdivo	Bristol Myers Squibb	\$9.0B	Oncology (PD-1)
2029	Darzalex	Johnson & Johnson	\$9.7B	Multiple Myeloma
2031	Dupixent	Sanofi / Regeneron	\$11.6B	Atopic Dermatitis
2032	Ozempic	Novo Nordisk	\$18.4B	Diabetes / GLP-1
2033	Biktarvy	Gilead	\$11.9B	HIV
2037	Trikafta	Vertex	\$8.9B	Cystic Fibrosis

### 3 EXECUTIVE OPPORTUNITIES | CEO & CMO — US & China

BioRich Inc. is actively identifying and recruiting Chief Executive Officers and Chief Medical Officers for portfolio companies and strategic ventures across the United States and China. As our BD&L network expands and new partnerships take shape, strong executive leadership is critical to commercializing next-generation drug assets.

Position	Region	Focus Area	Ideal Background	Contact
Chief Executive Officer	United States	Small molecule drug discovery for Alzheimer's disease	Background in CNS research within a global pharmaceutical company, along with management experience in BD&L and clinical development.	bd@biorichinc.com
Chief Medical Officer	Zhejiang Province, China	Leading the entire clinical R&D process, from strategy and trial design to execution, QC, and regulatory compliance	Phase I/II/III biologics trials end-to-end. In-depth knowledge of CFDA, China GCP, and ICH-GCP requirements. Proficiency in clinical trial monitoring.	bd@biorichinc.com

### 4 BD&L OPPORTUNITY BOARD | Buy-Side & Sell-Side Mandates

The following active mandates represent real, confidential interests from BioRich's global buy-side and sell-side partners. All inquiries handled directly through BioRich's BD&L desk. Matching assets will be introduced under NDA.

<b>#1</b>  IN-LICENSE	<p><b>NLRP3 Inhibitor — Brain-Penetrating Clinical-Stage Small Molecule</b></p> <p>US and European VCs and pharma companies are actively seeking Phase 1/2 small molecule programs targeting NLRP3 inflammasome with brain-penetrating CNS profile. Indications: neuroinflammation, Parkinson's, Alzheimer's, ALS. PCC through Phase 2 considered; academic, biotech, or CRO origin all welcome.</p> <p>Stage: <b>Phase 1 / Phase 2</b>   Area: <b>CNS / Neuroinflammation</b>   Contact: <a href="mailto:bd@biorichinc.com">bd@biorichinc.com</a></p>
-----------------------------	--

<b>#2</b>  NEWCO / INVEST	<p><b>US/EU Funds Seeking Chinese Assets for NewCo — Oncology, Autoimmune, CNS</b></p> <p>Multiple US and European venture funds are building NewCo structures around Chinese biotech assets. Preferred TAs: oncology (ADC, bispecifics, I/O), autoimmune (IL, JAK, NLRP3), CNS. Phase 1-ready or later preferred; strong preclinical packages considered. Recommendations warmly welcomed.</p> <p>Stage: <b>Phase 1-ready / Pre-IND</b>   Area: <b>Oncology · Autoimmune · CNS</b>   Contact: <a href="mailto:bd@biorichinc.com">bd@biorichinc.com</a></p>
---------------------------------	---

<b>#3</b>  M&A; / ACQUIRE	<p><b>State Fund: Controlling Stake Acquisition — Innovative Drug (RMB 30M Net Profit)</b></p> <p>A Chinese state-owned mother fund and a listed A-share company (separately) are each mandated to acquire controlling equity stakes in innovative drug companies with verified net profit of RMB 30M+. Listed or unlisted; broad therapeutic focus.</p>
---------------------------------	--

#4

IN-LICENSE

### Cell & Gene Therapy for Ophthalmology — Phase 1 / Phase 2 Programs

A well-capitalized company is seeking Phase 1/2 CGT programs for ophthalmic diseases: IRDs, wet AMD, Stargardt, LCA, and other serious retinal/corneal conditions. Both ex-China and China-rights deals considered; strong CMC and clinical data packages preferred.

Stage: **Phase 1 / Phase 2** | Area: **Ophthalmology / CGT** | Contact: [bd@biorichinc.com](mailto:bd@biorichinc.com)

#5

IN-LICENSE

### Orexin OX2R Antagonist (Sleep) + HK Company Seeking Ophthalmic Phase 2

US/EU pharma seeking OX2R antagonist programs for sleep insufficiency (PCC-Phase 2). Separately, a Hong Kong ophthalmic therapy company is seeking to in-license Phase 2 ophthalmic programs and related devices requiring only Greater China rights.

Stage: **PCC through Phase 2** | Area: **CNS (Sleep) · Ophthalmology** | Contact: [bd@biorichinc.com](mailto:bd@biorichinc.com)

#6

BUY-SIDE M&A;

### Chinese Company Seeking Oncology / Autoimmune Company or Small CRO

A Chinese pharma company is seeking to acquire oncology and/or autoimmune drug development companies, or small-to-mid CRO companies with specialty capabilities (oncology, immunology assays, translational biology). Global targets considered.

Stage: **Revenue-generating / Late-stage** | Area: **Oncology · Autoimmune · CRO** | Contact: [bd@biorichinc.com](mailto:bd@biorichinc.com)

28  
Total Assets13  
Partner Companies1  
Marketed Asset7  
Modality Types

BioRich International maintains an active out-licensing portfolio of **28 assets** spanning 7 modality types across oncology, neurology, metabolic diseases, and beyond. These assets are available for global licensing and partnership.

All

Marketed

Phase II

Phase I

Preclinical

Discovery

Stage	Asset / Program	Modality	Therapeutic Area	Indication	Rights Available
Marketed	BRX-001 (Commercialized)	Small Molecule	Oncology	Solid Tumors	Ex-China / Global
Phase II	BRX-021	Antibody (mAb)	Oncology	NSCLC / PD-L1	Global
	BRX-028	Bispecific Ab	Oncology	Gastric / HER2×PD-1	Ex-China
	BRX-035	Small Molecule	CNS	Alzheimer's Disease	US / EU
	BRX-047	ADC	Oncology	Triple-Negative Breast Cancer	Global
Phase I	BRX-053	PROTAC	Oncology	Hematological Malignancies	Global
	BRX-061	Small Molecule	Autoimmune	Psoriasis / IL-17 pathway	US / EU
	BRX-072	CGT (Gene Therapy)	Ophthalmology	IRD / Retinal Dystrophy	Global
	BRX-084	mRNA Therapeutic	Metabolic	NASH / Liver Disease	Ex-China
	BRX-091	Antibody (mAb)	CNS	Parkinson's Disease	US / EU
Preclinical	BRX-103	NLRP3 Inhibitor	Small Molecule / CNS	Neuroinflammation	Global
	BRX-112	Bispecific Ab	Oncology	Colorectal / EGFR×cMet	Ex-China
	BRX-118	LNP-mRNA	Nucleic Acid	Rare Metabolic Disease	Global
	BRX-124	Cell Therapy (CAR-T)	Oncology	B-cell Lymphoma	US / EU
	BRX-131	Small Molecule	Metabolic	Type 2 Diabetes / GLP-1	Asia-Pacific
	BRX-137	Gene Therapy (AAV)	Ophthalmology	Wet AMD	Greater China
	BRX-143	Orexin OX2R Antag.	CNS	Sleep Insufficiency	Global
Discovery	BRX-15x (Platform A)	AI-Designed Mol.	Oncology	Pan-KRAS / RAS	Global
	BRX-16x (Platform B)	saRNA Platform	Vaccines / Infectious Dis	eBarsoead	Global
	BRX-17x	Small Molecule	Autoimmune	JAK/ROCK Dual Inhib.	Ex-China
	For full portfolio details visit <a href="#">our website</a> BioRic				

# Full Out-Licensing Portfolio — Browse All 28 Assets

Out License | BioRich International



## Portfolio by Modality Type

Modality	# Assets	Key Therapeutic Areas	Stage Range
Small Molecule	9	CNS, Oncology, Metabolic, Autoimmune	Discovery & Marketed
Monoclonal Antibody	5	Oncology, CNS, Autoimmune	Phase I & Phase II
Bispecific Antibody	3	Oncology (GI, CRC, NSCLC)	Discovery & Phase II
ADC	2	Oncology (TNBC, Hematology)	Phase I & Phase II
Cell & Gene Therapy	3	Ophthalmology, Oncology (CAR-T)	Preclinical & Phase I
mRNA / Nucleic Acid	3	Metabolic, Vaccines, Rare Disease	Discovery & Phase I
PROTAC / Degradator	3	Oncology	Phase I

For detailed data packages, clinical summaries, and partnership terms, please contact BioRich's BD&L team at [bd@biorichinc.com](mailto:bd@biorichinc.com) or visit the full portfolio at [www.biorichinc.com/out-licensing](http://www.biorichinc.com/out-licensing)

**BioRich Inc. | [www.biorichinc.com](http://www.biorichinc.com) | [bd@biorichinc.com](mailto:bd@biorichinc.com)**

Connecting Innovation | Bridging Global Partnerships | Advancing Drug Development

© 2026 BioRich Inc. All rights reserved. | Out-License Portfolio: [www.biorichinc.com/out-licensing](http://www.biorichinc.com/out-licensing)

*Disclaimer: This newsletter is for informational purposes only. Deal values represent disclosed or estimated figures from public sources. Portfolio asset details are indicative. BioRich Inc. does not guarantee accuracy or completeness. Not investment advice*